These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9440812)

  • 1. Constitutive activity of glucagon receptor mutants.
    Hjorth SA; Orskov C; Schwartz TW
    Mol Endocrinol; 1998 Jan; 12(1):78-86. PubMed ID: 9440812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The third cytoplasmic domain of the GLP-1[7-36 amide] receptor is required for coupling to the adenylyl cyclase system.
    Takhar S; Gyomorey S; Su RC; Mathi SK; Li X; Wheeler MB
    Endocrinology; 1996 May; 137(5):2175-8. PubMed ID: 8612565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Point mutations in the first and third intracellular loops of the glucagon-like peptide-1 receptor alter intracellular signaling.
    Heller RS; Kieffer TJ; Habener JF
    Biochem Biophys Res Commun; 1996 Jun; 223(3):624-32. PubMed ID: 8687446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence to support a spectrum of active states for the glucagon receptor.
    Strudwick N; Bhogal N; Evans NA; Blaney FE; Findlay JB
    Biochem Soc Trans; 2004 Dec; 32(Pt 6):1037-9. PubMed ID: 15506957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutive activation of the human vasoactive intestinal peptide 1 receptor, a member of the new class II family of G protein-coupled receptors.
    Gaudin P; Maoret JJ; Couvineau A; Rouyer-Fessard C; Laburthe M
    J Biol Chem; 1998 Feb; 273(9):4990-6. PubMed ID: 9478946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences.
    Azizeh BY; Shenderovich MD; Trivedi D; Li G; Sturm NS; Hruby VJ
    J Med Chem; 1996 Jun; 39(13):2449-55. PubMed ID: 8691441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The human vasoactive intestinal Peptide/Pituitary adenylate cyclase activating peptide receptor 1 (VPAC1): constitutive activation by mutations at threonine 343.
    Gaudin P; Couvineau A; Rouyer-Fessard C; Maoret JJ; Laburthe M
    Biochem Biophys Res Commun; 1999 Jan; 254(1):15-20. PubMed ID: 9920725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of phenylalanine at position 6 in glucagon's mechanism of biological action: multiple replacement analogues of glucagon.
    Azizeh BY; Ahn JM; Caspari R; Shenderovich MD; Trivedi D; Hruby VJ
    J Med Chem; 1997 Aug; 40(16):2555-62. PubMed ID: 9258362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: evidence for difference in the structure-function relationship.
    Nicole P; Du K; Couvineau A; Laburthe M
    J Pharmacol Exp Ther; 1998 Feb; 284(2):744-50. PubMed ID: 9454823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of specific extracellular domains of the glucagon receptor in ligand binding and signaling.
    Unson CG; Wu CR; Jiang Y; Yoo B; Cheung C; Sakmar TP; Merrifield RB
    Biochemistry; 2002 Oct; 41(39):11795-803. PubMed ID: 12269822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cysteine residues are involved in structure and function of melanocortin 1 receptor: Substitution of a cysteine residue in transmembrane segment two converts an agonist to antagonist.
    Frändberg PA; Doufexis M; Kapas S; Chhajlani V
    Biochem Biophys Res Commun; 2001 Mar; 281(4):851-7. PubMed ID: 11237737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low level cyclic adenosine 3',5'-monophosphate accumulation analysis of [des-His1, des- Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists.
    Van Tine BA; Azizeh BY; Trivedi D; Phelps JR; Houslay MD; Johnson DG; Hruby VJ
    Endocrinology; 1996 Aug; 137(8):3316-22. PubMed ID: 8754757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspartate 196 in the first extracellular loop of the human VIP1 receptor is essential for VIP binding and VIP-stimulated cAMP production.
    Du K; Nicole P; Couvineau A; Laburthe M
    Biochem Biophys Res Commun; 1997 Jan; 230(2):289-92. PubMed ID: 9016768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scanning of the glucagon-like peptide-1 receptor localizes G protein-activating determinants primarily to the N terminus of the third intracellular loop.
    Mathi SK; Chan Y; Li X; Wheeler MB
    Mol Endocrinol; 1997 Apr; 11(4):424-32. PubMed ID: 9092794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness.
    Beinborn M; Worrall CI; McBride EW; Kopin AS
    Regul Pept; 2005 Aug; 130(1-2):1-6. PubMed ID: 15975668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutive activation of the cyclic adenosine 3',5'-monophosphate signaling pathway by parathyroid hormone (PTH)/PTH-related peptide receptors mutated at the two loci for Jansen's metaphyseal chondrodysplasia.
    Schipani E; Jensen GS; Pincus J; Nissenson RA; Gardella TJ; Jüppner H
    Mol Endocrinol; 1997 Jun; 11(7):851-8. PubMed ID: 9178745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural motifs of importance for the constitutive activity of the orphan 7TM receptor EBI2: analysis of receptor activation in the absence of an agonist.
    Benned-Jensen T; Rosenkilde MM
    Mol Pharmacol; 2008 Oct; 74(4):1008-21. PubMed ID: 18628402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the cAMP pathway by the TSH receptor involves switching of the ectodomain from a tethered inverse agonist to an agonist.
    Vlaeminck-Guillem V; Ho SC; Rodien P; Vassart G; Costagliola S
    Mol Endocrinol; 2002 Apr; 16(4):736-46. PubMed ID: 11923470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational analysis of the highly conserved arginine within the Glu/Asp-Arg-Tyr motif of the alpha(1b)-adrenergic receptor: effects on receptor isomerization and activation.
    Scheer A; Costa T; Fanelli F; De Benedetti PG; Mhaouty-Kodja S; Abuin L; Nenniger-Tosato M; Cotecchia S
    Mol Pharmacol; 2000 Feb; 57(2):219-31. PubMed ID: 10648631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pleiotropic effects of substitutions of a highly conserved leucine in transmembrane helix III of the human lutropin/choriogonadotropin receptor with respect to constitutive activation and hormone responsiveness.
    Shinozaki H; Fanelli F; Liu X; Jaquette J; Nakamura K; Segaloff DL
    Mol Endocrinol; 2001 Jun; 15(6):972-84. PubMed ID: 11376115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.